Dexus Industria REIT.

DXI

Dexus Industria REIT is an Australian real estate investment trust, which engages in interests in a workspace focused portfolio of several established, industrial, technology park and business park assets. The company is headquartered in Sydney, New South Wales. The company went IPO on 2013-12-03. The Trust is primarily engaged in investing in industrial warehouses located across Sydney, Melbourne, Brisbane, Perth and Adelaide. The Trust’s investment property portfolio consists of approximately 91 properties valued at $1.4 billion and is located across the major Australian cities. The company has a target gearing range of 30 - 40%. Its properties include 12 Church Road, Moorebank; 1-3 Westrac Drive, Newcastle; 7 Clunies Ross Court and 17-19 McKechnie Drive, Eight Mile Plains; 8 Clunies Ross Court and 9 McKechnie Drive, Eight Mile Plains; 18 Brandl Street, Eight Mile Plains; 37 Brandl Street, Eight Mile Plains; 88 Brandl Street, Eight Mile Plains; Brisbane Technology Park, Central, Eight Mile Plains; 9 Boron Street, Narangba; 60 Grindle Road, Wacol; 5 Butler Boulevard, Adelaide Airport; 5b Butler Boulevard, Adelaide Airport, and 45-65 O'Briens Road, Corio. Its manager is Dexus Asset Management Limited.

DXN Limited

DXN

DXN Ltd. engages in the construction of data center modules and sale to third-party data center owners. The Company’s core business is designing, engineering, manufacturing, maintaining and operating data centers. Its divisions include Modular Division and Data Centre Operations. The Modular Division designs, engineers, manufactures and deploys EDGE facilities and critical DC infrastructure. The Data Centre Operations division operates, maintains and markets data centers and critical infrastructure for its own DXN data centers, as well as its modular customers. Its solutions include DXN Modules/ Built to order, Edge Data Centers, Micro Edge, DXN-SYDO1, SDC Darwin and others. Its Edge Data Centre solutions are designed and deployed to meet its customers' individual needs at the Edge. Its DXN-SYD01 has been built to offer a complete and comprehensive colocation solution. Its range of services includes engineering, project management, data center management and maintenance and support.

Dimerix Limited

DXB

Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. The company develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The firm is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.